✦ LIBER ✦

Efficacy and Safety of Omalizumab in Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU): Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial

✍ Scribed by Casale, Thomas; Maurer, Marcus; Hsieh, Hsin-Ju; Canvin, Janice; Saini, Sarbjit S.; Grattan, Clive; Gimenez-Arnau, Ana; Kaplan, Allen P.; Rosen, Karin

Book ID: 123074791
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 50 KB
Volume: 131
Category: Article
ISSN: 1097-6825
DOI: 10.1016/j.jaci.2012.12.1546

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Baseline Characteristics of Patients wit

Baseline Characteristics of Patients with Refractory Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Enrolled in a Phase III, Randomized, Placebo-Controlled Trial of Omalizumab

✍ Rosen, Karin; Hsieh, Hsin-Ju; Georgiou, Panayiotis; Casale, Thomas; Maurer, Marc 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 38 KB

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria

✍ M. Magerl; M. Rother; T. Bieber; T. Biedermann; J. Brasch; R. Dominicus; N. Hunz 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 300 KB

Efficacy and safety of desloratadine 5 m

Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial*

✍ Eugene Monroe; Albert Finn; Piyush Patel; Robinson Guerrero; Paul Ratner; David 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 121 KB

Efficacy and safety of golimumab in pati

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial

✍ Robert D. Inman; John C. Davis Jr.; Désirée Van Der Heijde; Laura Diekman; Joach 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 2 views

## Abstract ## Objective To evaluate the efficacy and safety of golimumab in patients with ankylosing spondylitis (AS) in the GO‐RAISE study. ## Methods Patients with active AS, a Bath AS Disease Activity Index (BASDAI) score ≥4, and a back pain score of ≥4 were randomly assigned in a 1.8:1.8:1

Efficacy and Safety of Omalizumab in Pat

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study

✍ Saini, Sarbjit S; Bindslev-Jensen, Carsten; Maurer, Marcus; Grob, Jean-Jacques; 📂 Article 📅 2015 🏛 Nature Publishing Group 🌐 English ⚖ 309 KB

Efficacy and safety of omalizumab in pat

Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on h 1 antihistamines: A randomized, placebo-controlled study

✍ Saini, Sarbjit S. (author);Bindslev-Jensen, Carsten (author);Maurer, Marcus (aut 📂 Article 📅 2015 🏛 Nature Publishing Group 🌐 English ⚖ 309 KB